- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03295799
Patient-Centred Care for Warfarin Management: A Pilot Study to Transition Care to High Risk Patients
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
50 patients will receive a cover letter outlining their random selection for this study, along with the patient information sheet and consent form (with a return addressed, postage paid envelope). Patients will be encouraged to contact the AC and speak with the Principal Investigator (TB) regarding the research study, and all questions will be addressed. We will continue this mailing process until a total of 50 patients have consented to study. PSM within the context of this study may use either POC technology or standard venipuncture with the patient accessing the laboratory for results. After receipt of consent, patients will be required to pass a foundational exam (outlining the basics of anticoagulation therapy, most of which should be simple review for the patients managed within our AC).4,10 Upon successfully passing this multiple choice exam, patients will be randomized to AC care (with no changes implemented) or to PSM.
PSM Phase I: Preparatory Phase of Patient Training (~6weeks) During the initial preparatory phase lasting 6 weeks + 2 weeks, the AC will create a patient specific warfarin dosing nomogram, discuss the same with the patient and ensure clear understanding, while working through various scenarios with the patient (Appendix 1). The AC will ensure the patient has an established system to both retrieve INR results (via POC technology or standard venipuncture) as well as to document the INR results, warfarin dosing, any pertinent assessment factors, and next date to test the INR. The AC will empower the patient to be proactive with coming up with warfarin dose changes during this preparatory phase.
PSM Phase II: Patient Practical Training:
The AC will enrol the patient into the PSM practical training phase (lasting 3 months + 1 month). At this time, the patient will retrieve their result and establish a future warfarin dose and follow-up plan. This information will be transmitted to a single AC team member. Contact with anotherdiscussed with an AC team member and the ultimate dosing decision will be tracked to ascertain concordance of the patient's original plan to what was implemented during the follow-up visit with the to perform standard AC teamcare and management will occur, thereby enabling comparison of the patient's plan and the AC plan. During this phase, the AC plan will be implemented. At the end of this phase, patients must pass a multiple choice exam that provides practical cases targeting warfarin dose adjustment with next scheduled follow-up visit, and will then be positioned into the PSM arm of the study.
Patient Self-Management During the PSM phase (6 months +/- 1 month), contact will occur with the AC monthly to retrieve INR results and warfarin dose adjustments (information from the patient-based charting system). Key points of contact between the patient and the AC will be required, such as: INR results either > 5.0 or 0.5 INR units below the lower limit of their desired target INR range, initiation of interacting medications, illness, etc. Patients not demonstrating the ability to self-manage their own warfarin therapy will be encouraged to cross-over to AC care. At the end of 6 months, patient choice of AC care or PSM will be identified.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Alberta
-
Edmonton, Alberta, Canadá, T6G 2J3
- University of Alberta
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- mechanical heart valve as the indication for warfarin
- > 16 years of age
- Warfarin therapy managed by the AC for at least the preceding 6 months
- Anticipated duration of warfarin therapy to be lifelong
- Previously adherent with medication
- Competence judged by demonstrated ability to use drug-adjustment nomograms
Exclusion Criteria:
• Severe psychiatric disease
- Significant language barrier
- Clinician's judgment that the patient would be a poor candidate for study (with reason specified)
- Known or anticipated procedure/surgery/intervention in the next year
- Active participation in another study
- Lack of access to the internet / email
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Pesquisa de serviços de saúde
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Patient Self-Management
Patients will go through a preparatory phase (creation of warfarin dosing chart, process for documentation and retrieval of labs), a practical training phase (formulate warfarin management plan with support) and then perform patient-self management of their own warfarin.
|
Patient will manage their own warfarin therapy.
|
|
Sem intervenção: Anticoagulation Clinic Care
Patients will not have their care altered, and will continue to be managed by our Anticoagulation Clinic.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
The change in quality of life score (using the validated instruments DASS and Sawicki scale) between PSM and AC care.
Prazo: 6 months
|
Duke Anticoagulation Satisfaction Scale (DASS) and Sawicki Scale
|
6 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
The proportion of patients completing PSM
Prazo: 9 months
|
Beginning from consent and capturing stage at which patients withdrew (if applicable) namely the preparatory and practical training phases or PSM as well as those electing to continue PSM after study
|
9 months
|
|
Difference in the time in therapeutic INR range between those randomized to AC care versus PSM.
Prazo: 6 months
|
Time in range will be calculated using the Rosendaal method.
|
6 months
|
|
The rate of ER and hospitalization for anticoagulant and non-anticoagulant reasons between AC care and PSM.
Prazo: 6 months
|
presentations to hospital
|
6 months
|
|
The amount of time spent by the AC team for the AC group relative to the PSM group.
Prazo: 9 months
|
the number of minutes taken for each arm, as a measure of resource use within the AC team.
|
9 months
|
|
Amongst the PSM group, to determine if strategies for self-managing warfarin therapy have made patients do so for other chronic diseases.
Prazo: 6 months
|
a descriptive measure of translation of proactive management
|
6 months
|
|
Number of participants in AC care vs PSM that are dead at 5 years.
Prazo: 5 years following study completion
|
mortality measure
|
5 years following study completion
|
|
Number of encounters in the PSM group that put forward warfarin dosing that is concordant with that of the AC and to provide descriptions of warfarin dose changes.
Prazo: 3 months
|
assessed prior to entering the PSM phase
|
3 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Tammy Bungard, BSP, PharmD, University of Alberta
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- Pro00052090
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Qualidade de vida
-
Indiana UniversityRecrutamentoUltrassom Point of Care (POCUS)Estados Unidos
-
Aalborg UniversityConcluídoUltrassonografia Point of Care (POCUS)Dinamarca
-
Asociacion Española Primera en SaludIntensive Care Unit Pasteur HospitalConcluídoUltrassom Point of CareUruguai
-
Aga Khan UniversityThe Hospital for Sick Children; Grand Challenges CanadaDesconhecidoUltrassom Point of CarePaquistão
-
Medical University of WarsawRecrutamentoUltrassom Point of Care (POCUS) | Hemodynamic Assessment | Bedside UltrasonographyPolônia
-
University of BolognaRecrutamentoHemodiálise | Avaliação de Volume | Ultrassom Point of Care (POCUS)Itália
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute of Mental Health...ConcluídoTransgênero, HIV Continuum of CareEstados Unidos
-
Hospital for Special Surgery, New YorkConcluídoPeptídeo 1 semelhante ao glucagon | Ultrassom Gástrico | Ultrassom Point of CareEstados Unidos, Canadá
-
Johann Wolfgang Goethe University HospitalConcluídoFormação de Coágulos e Agregação de Plaquetas em Testes Point of CareAlemanha
-
Queens College, The City University of New YorkRecrutamentoPublicação de artigos submetidos ao American Journal of Public HealthEstados Unidos
Ensaios clínicos em Patient Self-Management
-
University of WashingtonNational Center for Complementary and Integrative Health (NCCIH)Concluído
-
Centre Hospitalier Annecy GenevoisConcluídoInfecções por HIVFrança
-
Lady Davis InstituteConcluído
-
Lady Davis InstituteConcluídoEsclerose Sistêmica | EsclerodermiaCanadá
-
DMG Dental Material Gesellschaft mbHUniversity of Coimbra; University Arthur Sá Earp NetoAinda não está recrutandoCáries dentáriasBrasil, Portugal
-
Brigham and Women's HospitalNational Institutes of Health (NIH); National Library of Medicine (NLM)DesconhecidoCâncer | Perda de audição | Cardiomiopatia hipertróficaEstados Unidos, Canadá
-
Life Seal Vascular Inc.Auckland City HospitalRecrutamentoAneurisma da aorta abdominalNova Zelândia
-
Shirley Ryan AbilityLabCoapt, LLCAtivo, não recrutandoAmputação de membro inferior abaixo do joelho (lesão) | Amputação de membro inferior acima do joelho (lesão) | Amputação | Dor do membro fantasma | Dor fantasma | Sensação Fantasma | Joelho para Amputação de Membro Inferior | Amputação de membro superior abaixo do cotovelo (lesão) | Dor fantasma após... e outras condiçõesEstados Unidos
-
Robert SimpsonAinda não está recrutandoEsclerose múltipla | Auto compaixãoCanadá
-
Brigham and Women's HospitalConcluídoSíndrome do Idoso Frágil | Fragilidade | Envelhecimento | Síndrome da FragilidadeEstados Unidos